CAJ | 학술논문

目的探讨盐酸特拉唑嗪联合前列舒通胶囊治疗Ⅲ型前列腺炎的临床效果.方法将120例Ⅲ型前列腺炎患者平均分为观察组和对照组,分别给予盐酸特拉唑嗪(2mg,每晚1次)+前列舒通胶囊(3粒,每天3次)和盐酸特拉唑嗪(2mg,每晚1次)治疗,8周后按照美国国立卫生研究所(NIH)制定的前列腺症状评分标准( CPSI)、生活质量(QOL)评分及前列腺液常规.结果经过8周的治疗,观察组和对照组的NIH - CPSI评分、QOL评分及EPS常规中白细胞数目均有显著下降(P＜0.01),但观察组下降的程度均较对照组明显(P＜0.01).结论盐酸特拉唑嗪联合前列舒通胶囊治疗Ⅲ型前列腺炎比单用盐酸特拉唑嗪疗效明显,值得临床推广.
목적 탐토염산특랍서진연합전렬서통효낭치료Ⅲ형전렬선염적림상효과.방법 장120례Ⅲ형전렬선염환자평균분위관찰조화대조조,분별급여염산특랍서진(2mg,매만1차)+전렬서통효낭(3립,매천3차)화염산특랍서진(2mg,매만1차)치료,8주후안조미국국립위생연구소(NIH)제정적전렬선증상평분표준( CPSI)、생활질량(QOL)평분급전렬선액상규.결과 경과8주적치료,관찰조화대조조적NIH - CPSI평분、QOL평분급EPS상규중백세포수목균유현저하강(P＜0.01),단관찰조하강적정도균교대조조명현(P＜0.01).결론 염산특랍서진연합전렬서통효낭치료Ⅲ형전렬선염비단용염산특랍서진료효명현,치득림상추엄.
Objectives To investigate the clinical effects of the terazosin Qianlieshu capsule treatment of type Ⅲ prostatitis.Methods 120 patients with type Ⅲ prostatitis patients were divided into observation group and control group were treated with terazsin (2 mg,1 night) + (3 capsules Qianlieshu capsule three times daily) and hydrochloric acid terazosin (2 mg,1 night) treatment,after 8 weeks in accordance with the U.S.National Institutes of Health (NIH) to develop prostate symptom score ( CPSI ),quality of life (QOL) score and prostatic fluid routine.Results After eight weeks of treatment,observation group and control group of the NIH-CPSI score,QOL in score and EPS conventional leukocyte count are significantly decreased( P ＜0.01 ),but the degree of decline in the observation group than in the control group significantly( P ＜ 0.01 ).Conclusions Terazosin forefront of spironolactone capsules in treatment of prostatitis type Ⅲ terazosin efficacy than the single is worthy of clinical.